Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07575568Not ApplicableNot Yet Recruiting

Revascularization With Modification Using Definitive IVL and Serration Remodeling for Optimal Lumen

Role: lead

NCT06687590Recruiting

Serranator POINT FORCE Registry

Role: lead

NCT06434194Not ApplicableRecruiting

Serrantor OCT Study

Role: lead

NCT05161039Not ApplicableUnknown

Serranator Recoil Study

Role: lead

NCT03693963Not ApplicableCompleted

The PRELUDE BTK Study

Role: lead

NCT03538392Withdrawn

Serranator® Alto Post Market Clinical Follow Up (PMCF) Study

Role: lead

NCT03001700Not ApplicableCompleted

PRospective Study for the TrEatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Using the Serranator DevicE

Role: lead

All 7 trials loaded